Skip to main content

Table 3 Summary of subgroup analysis for prophylaxis efficacy

From: Utility of posaconazole therapeutic drug monitoring and assessment of plasma concentration threshold for effective prophylaxis of invasive fungal infections: a meta-analysis with trial sequential analysis

Subgroup   Cut-off value(mg/L) OR(95% CI) No. of studies No. of participants in experimental group No. of participants in control group I2% P
Underlying disease Cardiothoracic transplant Css ≥ 0.5 vs. Css < 0.5 1.16 [0.05, 26.94] 2 16/24 6/11 49 0.92
Hematological malignancy Css ≥ 0.5 vs. Css < 0.5 2.06 [1.12, 3.82] 18 619/638 333/370 0 0.02
Underlying disease Cardiothoracic transplant Css ≥ 0.7 vs. Css < 0.7 2.00 [0.09, 44.35] 1 1/4 1/7 NA 0.66
  Hematological malignancy Css ≥ 0.7 vs. Css < 0.7 1.84 [0.92, 3.68] 14 585/608 438/479 0 0.09
  1. NA not available